哮喘及哮喘用药对COVID-19患者预后的影响
该研究基于韩国健康保险审查评价院链接医疗索赔数据,纳入截至2020年5月15日经SARS-CoV-2 RNA-PCR确诊的7590例COVID-19患者,其中218例(2.9%)有基础哮喘。结果显示哮喘患者死亡率(7.8%)显著高于其他患者(2.8%;p<0.001),但校正后哮喘并非COVID-19临床结局的独立危险因素,哮喘用药及严重程度一般不影响结局;口服短效β2受体激动剂是增加总医疗费用负担的独立因素,第5级哮喘患者住院时间较第1级显著延长。
要点
- 哮喘患者COVID-19死亡率7.8%,显著高于其他患者的2.8%(p<0.001)。
- 校正后哮喘并非COVID-19不良临床结局的独立危险因素。
- 口服短效β2受体激动剂是增加总医疗费用负担的独立因素。
核心结论
- 哮喘导致COVID-19结局较差,但基础哮喘、哮喘用药及哮喘严重程度一般并非COVID-19不良临床结局的独立因素。
研究设计与样本
- 基于韩国健康保险审查评价院链接医疗索赔数据的回顾性研究,纳入截至2020年5月15日经SARS-CoV-2 RNA-PCR确诊的7590例COVID-19患者。
- 哮喘及哮喘严重程度依据诊断代码和哮喘用药史定义,严重程度采用全球哮喘防治创议(GINA)建议的分级。
主要发现
- 7590例COVID-19患者中218例(2.9%)有基础哮喘。
- 有基础哮喘的COVID-19患者总医疗费用显著高于其他患者。
- 有基础哮喘的COVID-19患者死亡率为7.8%,显著高于其他患者的2.8%(p<0.001)。
- 校正后哮喘并非COVID-19临床结局的独立危险因素,哮喘用药及哮喘严重程度也未影响COVID-19临床结局。
- 口服短效β2受体激动剂使用是增加总医疗费用负担的独立因素;第5级哮喘患者住院时间较第1级哮喘患者显著延长(单因素和多因素分析均显著)。
临床怎么用
- 临床中不应仅因患者有基础哮喘即将其视为COVID-19不良结局的高危独立因素。
- 需关注哮喘患者COVID-19医疗费用负担可能更高,尤其是使用口服短效β2受体激动剂者。
- 第5级哮喘患者感染COVID-19后住院时间可能更长,需加强住院管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread worldwide rapidly. However, the effects of asthma, asthma medication and asthma severity on the clinical outcomes of COVID-19 have not yet been established. METHODS: The study included 7590 de-identified patients, who were confirmed to have COVID-19 using the severe acute respiratory syndrome coronavirus 2 RNA-PCR tests conducted up to May 15, 2020; we used the linked-medical claims data provided by the Health Insurance Review and Assessment Service. Asthma and asthma severity (steps suggested by the Global Initiative for Asthma) were defined using the diagnostic code and history of asthma medication usage. RESULTS: Among 7590 COVID-19 patients, 218 (2.9%) had underlying asthma. The total medical cost associated with COVID-19 patients with underlying asthma was significantly higher than that of other patients. Mortality rate for COVID-19 patients with underlying asthma (7.8%) was significantly higher than that of other patients (2.8%; p<0.001). However, asthma was not an independent risk factor for the clinical outcomes of COVID-19 after adjustment, nor did asthma medication use and asthma severity affect the clinical outcomes of COVID-19. However, use of oral short-acting β2-agonists was an independent factor to increase the total medical cost burden. Patients with step 5 asthma showed significant prolonged duration of admission compared to those with step 1 asthma in both univariate and multivariate analysis. CONCLUSIONS: Asthma led to poor outcomes of COVID-19; however, underlying asthma, use of asthma medication and asthma severity were not independent factors for poor clinical outcomes of COVID-19, generally.
引用
- Choi YJ, Park JY, Lee HS, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J. 2021. PMID: 32978309. doi:10.1183/13993003.02226-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。